Navigation Links
FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
Date:6/15/2009

BOSTON, June 15 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.

The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School, at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT).

BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually.

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or impli
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
2. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
3. Michael Simmons, DMD presented a poster at the American Academy of Dental Sleep Medicine Meeting
4. WebMD to Present at Jefferies 3rd Annual Healthcare Conference
5. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
6. First-Ever Standardized Scales to Measure the Skins Aging Process Are Presented at THE Aesthetic Show
7. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
8. IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference
9. NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
10. Kensey Nash to Present at the Jefferies 3rd Annual Healthcare Conference
11. Latest trinational report presents most complete picture of North American industrial pollution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... GA (PRWEB) , ... June 30, 2015 , ... After ... by the U.S. Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for ... with an SPF rating of 35, hits the market just in time to help ...
(Date:6/30/2015)... Tennessee (PRWEB) , ... June ... ... of CorrectChemo®, the drug response profiling test to help oncologists provide personalized ... , “The CorrectChemo® assay provides the oncologist with valuable insight on ...
(Date:6/30/2015)... ... 30, 2015 , ... iData Research ( http://www.idataresearch.com ), the ... insurance policy tracking and analysis service. Reimbursement Tracker ™ enables medical device, ... in real-time from hundreds of insurance companies covering over 60,000 policies. , ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... medical imaging. The company provides high quality record management services for patient records. ... This is normally required by physicians and clinics. , With the increase ...
(Date:6/30/2015)... California (PRWEB) , ... June 30, 2015 , ... ... applauds Congressmen Joe Kennedy III (D-MA) and Danny Davis (D-IL) for writing to ... up its investigation into the nation’s largest behavioral healthcare system, Universal Health Services ...
Breaking Medicine News(10 mins):Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5
... Golf can be a good investment for the health, according ... Institutet. The death rate for golfers is 40 per cent ... and socioeconomic status, which correspond to a 5 year increase ... safest. , It is a well-known fact that exercise ...
... 2008) Results from a pivotal Phase III ... oral, once-daily, investigational anticoagulant medication, was superior in ... total knee replacement (TKR) surgery. The head-to-head study ... enoxaparin, the current standard of care. , Data ...
... May 30 Lutronic, Inc., one of,the world,s ... today that its MOSAIC eCO2 system, the next ... the deep,ablative features of a CO2 laser, is ... With intuitive touch-screen software, the powerful MOSAIC ...
... May 30 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... been notified by,the American Stock Exchange (the "AMEX") ... for regaining compliance with the continued listing,standards and ... stock from the,Exchange by filing a delisting application ...
... less likely than white women to receive the radiation ... according to a study that Dana-Farber Cancer Institute researchers ... Society of Clinical Oncology in Chicago. , Although the ... that thousands of black and Hispanic breast cancer patients ...
... COLUMBUS, Ohio Medical researchers at The Ohio State ... a $34 million grant from the National Institutes of ... translational protocols that help identify and advance treatments for ... received by Ohio State. , The Ohio State University ...
Cached Medicine News:Health News:Golf prolongs life 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Colibri style shafts with delicate pointed 1 mm tips. Open serrated handle with dull finish....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: